Michael Gelband’s Arcutis Biotherapeutics ARQT Stock Holding History

Michael Gelband’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-242,457	Closed	-$3.79M	–	1450
2025 Q1	$3.79M	Buy	+242,457	New	+$3.42M	0.04%	505
2024 Q4	–	Sell	-323,701	Closed	-$3.01M	–	1500
2024 Q3	$3.01M	Sell	323,701 -789,881	-71%	-$7.79M	0.02%	585
2024 Q2	$10.4M	Buy	1,113,582 +891,360	+401%	+$8.06M	0.07%	246
2024 Q1	$2.2M	Buy	+222,222	New	+$1.66M	0.02%	664
2023 Q4	–	Sell	-33,545	Closed	-$178K	–	1447
2023 Q3	$178K	Buy	+33,545	New	+$285K	﹤0.01%	1539
2023 Q1	–	Sell	-65,995	Closed	-$977K	–	1734
2022 Q4	$977K	Buy	65,995 +18,940	+40%	+$331K	0.01%	955
2022 Q3	$899K	Buy	+47,055	New	+$1.07M	0.01%	1153

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Michael Gelband's ARQT Position: Q2 2025 in Review

Michael Gelband sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 242,457 shares — an estimated $3.79M sold.

Michael Gelband first reported a position in ARQT in Q3 2022 and held it in 7 quarters. The position peaked at $10.4M in Q2 2024. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

Michael Gelband reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
Michael Gelband sold 242,457 Arcutis Biotherapeutics shares in Q2 2025, an estimated $3.79M.
Michael Gelband first reported a position in Arcutis Biotherapeutics in Q3 2022 and held it in 7 quarters.
Michael Gelband's Arcutis Biotherapeutics position peaked at $10.4M in Q2 2024.
230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.